Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025

Core Insights - Immunovant reported its financial results for the second quarter ended September 30, 2025, highlighting significant advancements in its clinical programs and financial performance [1] Recent Highlights and Upcoming Milestones - The study of IMVT-1402 in uncontrolled Graves' disease (GD) patients demonstrated the first-ever potentially disease-modifying therapy with six-month off-treatment data [2][9] - IMVT-1402 is being developed for six indications, with ongoing potentially registrational trials in GD, myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat rheumatoid arthritis (D2T RA), and Sjögren's disease (SjD) [2][9] - Results from the open-label portion of the potentially registrational trial of IMVT-1402 in D2T RA and topline results from the proof-of-concept trial in cutaneous lupus erythematosus (CLE) are expected in 2026 [3] - Topline results from potentially registrational trials in GD, MG, and D2T RA are anticipated in 2027 [3] Financial Highlights for Fiscal Second Quarter - As of September 30, 2025, Immunovant's cash and cash equivalents totaled approximately $521.9 million, providing sufficient runway for announced indications through the GD readout expected in 2027 [4][9] - Research and development (R&D) expenses for the quarter were $114.2 million, an increase from $97.3 million in the same period of 2024, primarily due to clinical trial activities for IMVT-1402 [5][11] - General and administrative (G&A) expenses decreased to $17.5 million from $18.5 million year-over-year, attributed to streamlined administrative processes [6] Net Loss Analysis - The net loss for the quarter was $126.5 million ($0.73 per common share), compared to a net loss of $109.1 million ($0.74 per common share) in the prior year [8][14] - Non-GAAP net loss was $113.3 million for the quarter, compared to $96.5 million in the same period of 2024 [8] Financial Highlights for Fiscal Six Months - For the six months ended September 30, 2025, R&D expenses totaled $215.4 million, up from $172.7 million in the same period of 2024 [11][14] - G&A expenses for the six months increased to $43.5 million from $37.3 million year-over-year [12] - The net loss for the six months was $247.1 million ($1.43 per common share), compared to $196.3 million ($1.34 per common share) in the previous year [14]